7 results about "Squamous epithelial cell" patented technology

The three-dimensional propaganda and education model comprises a model main body, an identification assembly and a supporting base, the model main body is made of a transparent material, and an unqualified sputum specimen simulation unit (such as saliva and a polluted sputum specimen) and a qualified sputum specimen simulation unit (such as white viscous sputum, yellow viscous sputum and bloody sputum) are arranged in the model main body; each unit is of an independent cavity structure, and the sputum character is visually displayed by accurately controlling the color and viscosity and simulating particles (such as squamous epithelial cells or inflammatory cells); the identification assembly is used for clearly marking the type and the qualified standard through an identification board and a fluorescent coating; the supporting base provides stable placement. Through materialized comparison, the patient can quickly distinguish the sputum type, so that the retention quality is improved from the source, the percent of pass is remarkably improved, the nursing load is reduced, and the method has the advantages of intuition, standardization, high efficiency, safety and the like.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The application relates to the field of artificial intelligence medical technology and discloses an early esophageal cancer screening method and system based on artificial intelligence, which comprises the following steps: preparing an obtained esophageal epithelial cell sample of a subject into a single-layer cytological smear, generating an original digital pathology image through optical scanning; extracting independent cells therefrom, calculating local spatial moment parameters of the independent cells; determining the geometric principal axis direction and stretching degree of the independent cells based on the local spatial moment parameters; judging whether the stretching degree exceeds the length-width ratio benchmark constant of normal esophageal squamous epithelial cells, if yes, applying a local two-dimensional affine transformation to the independent cells along the geometric principal axis direction to offset the mechanical stretching deformation caused by sampling, and generating calibrated cell image data; inputting the calibrated cell image data into an artificial intelligence classification module, extracting cell pathological features based on a deep convolutional neural network, and outputting a screening diagnosis result. The application offsets cell deformation interference and improves screening accuracy.

The application belongs to the technical field of biomedicine, and specifically discloses a squamous cell carcinoma antigen determination kit and application, which comprises anti-reagent A, anti-reagent B and magnetic micro-particle reagent, wherein the anti-reagent A is a biotin-labeled squamous cell carcinoma antigen antibody; the anti-reagent B is an alkaline phosphatase-labeled squamous cell carcinoma antigen antibody; the squamous cell carcinoma antigen determination kit can effectively detect the concentration of squamous cell carcinoma antigen (SCC) in serum and plasma samples, and is mainly used for the treatment monitoring of cervical cancer, non-small cell carcinoma and the like, and has a wide application prospect.

The invention relates to a method for analyzing squamous epithelial cells. The method comprises the following steps: treating a sample containing the squamous epithelial cells for 1 min to 3 h by using an acidic reagent; acquiring optical information of the processed sample, wherein the optical information comprises a forward scattering light signal and a lateral scattering light signal; and distinguishing the basal layer cells from the sample and / or counting the basal layer cells according to the forward scattered light signal and the lateral scattered light signal. The invention also relates to an analyzer. The present application provides a method for efficiently and simply differentiating the type of squamous epithelial cells.

The application belongs to the technical field of bioengineering, and relates to a fluorescent probe for detecting squamous cell carcinoma antigen and application thereof. The application utilizes phage display technology to screen short peptides S1 and S2 which are specific to squamous cell carcinoma antigen and bind to the squamous cell carcinoma antigen. A cyclic fluorescent protein R-GECO1 is inserted into the short peptides S1 and S2, and a fluorescent probe with the structure of S1-R-GECO1-S2 is formed. The fluorescent probe provided by the application has relatively small protein molecular weight and is easy to mature. The fluorescent probe has large dynamic change of fluorescence and good specificity, and can detect squamous cell carcinoma antigen in and out of cells.

The invention relates to the technical field of immunoassay detection, in particular to a homogeneous chemiluminescence determination kit for squamous cell carcinoma antigen. The kit comprises a reagent 1 and a reagent 2, wherein the reagent 1 comprises a squamous cell carcinoma antigen-antibody 1 and a donor marker; and the reagent 2 comprises a squamous cell carcinoma antigen-antibody 2 and a receptor marker. The squamous epithelial cell carcinoma antigen-antibody 1 and the donor marker are mixed to obtain a reagent 1, and the squamous epithelial cell carcinoma antigen-antibody 2 and the receptor marker are mixed to obtain a reagent 2. The method is high in sensitivity, free of cleaning and separation, suitable for clinically, rapidly, efficiently and accurately measuring the squamous epithelial cell carcinoma antigen, wide in detection concentration range and capable of achieving high-sensitivity and high-accuracy measurement of the squamous epithelial cell carcinoma antigen.